Adaptimmune announces first ever clinical trial with engineered T cells designed to clear HIV infection

Researchers at Adaptimmune and the University of  Pennsylvania announce the approval of an IND and opening for enrolment of the first ever study using engineered T cells to treat HIV

Technology

Adoptive T cell therapy

Adoptive therapy is the process of taking blood cells from a patient, manipulating them in some way to improve their therapeutic potential when outside the body (i.e. ex-vivo), and returning them to the same patient.

Adaptimmune focuses on adoptive T cell therapy because T-lymphocytes or T cells Find out more

R & D

HIV RESEARCH

HIV, like many viruses, often manages to escape complete destruction by the immune system through mutation of the peptide antigens presented by surface HLA proteins.  These ‘escape mutants’ are poorly recognised by the T cells that controlled the original infection, allowing the mutated virus time to replicate and spread. Find out more

Adaptimmune Ltd, 57c Milton Park, Abingdon, Oxfordshire, OX14 4RX, UK

© 2010 Adaptimmune Ltd - Registered in England No: 6456741

Tel: +44 (0) 1235 438 642 | Fax: +44 (0) 1235 438 607

Email: info@adaptimmune.com

• Home
• Management
• Technology
• R & D
• IP
• News
• Recruitment
• Links
• Contact Us